Syndecan 4, galectin 2, and death receptor 3 (DR3) as novel proteins in pathophysiology of preeclampsia

References

• Kim YJ. Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci. 2013;56(1):2–7.
   PubMedGoogle Scholar
• Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69(1):1–7.
   PubMed Web of Science ®Google Scholar
• Charkiewicz K, Jasinska E, Laudanski P. Identification of proteomic biomarkers of preeclampsia using protein microarray and tandem mass spectrometry. Postep Hig Med Dosw. 2015;69:562–570.
   Web of Science ®Google Scholar
• Lee ES, Oh MJ, Jung JW, et al. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci. 2007;22(1):94–98.
   PubMed Web of Science ®Google Scholar
• Charkiewicz K, Goscik J, Blachnio-Zabielska A, et al. Sphingolipids as a new factor in the pathomechanism of preeclampsia – mass spectrometry analysis. PLoS One. 2017;12(5):e0177601.
   PubMed Web of Science ®Google Scholar
• Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol. 2013;94(2):247–257.
   PubMed Web of Science ®Google Scholar
• Bounds KR, Newell-Rogers MK, Mitchell BM. Four pathways involving innate immunity in the pathogenesis of preeclampsia. Front Cardiovasc Med. 2015;2:20.
   PubMedGoogle Scholar
• Laudanski P, Zbucka-Kretowska M, Charkiewicz K, et al. Maternal plasma and amniotic fluid chemokines screening in fetal Down syndrome. Mediat Inflamm. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Laudanski P, Lemancewicz A, Kuc P, et al. Chemokines profiling of patients with preterm birth. Mediat Inflamm. 2014;2014:1.
   Web of Science ®Google Scholar
• Zbucka-Kretowska M, Charkiewicz K, Czerniecki J, et al. Amniotic fluid angiogenic and inflammatory factor profiling in foetal Down syndrome. Fetal Diagn Ther. 2018;44(1):44–50.
   PubMed Web of Science ®Google Scholar
• Charkiewicz K, Zbucka-Kretowska M, Goscik J, et al. Brief communication: maternal plasma autoantibodies screening in fetal Down syndrome. J Immunol Res. 2016;2016:1.
   Web of Science ®Google Scholar
• Chambers MJ, Freeny A, Heiberger MR. Analysis of variance; designed experiments. Statistical Models in S. Pacific Grove (CA): Wadsworth & Brooks: Cole; 1992.
   Google Scholar
• Wilcoxin F. Probability tables for individual comparisons by ranking methods. Biometrics. 1947;3(3):119–122.
   PubMed Web of Science ®Google Scholar
• Shapiro SS, Francia RS. An approximate analysis of variance test for normality. J Am Stat Assoc. 1972;67(337):215–216.
   Web of Science ®Google Scholar
• Levene H. Robust tests for equality of variances. Contributions to Probability and Statistics: essays in Honor of Harold Hotelling. Vol. 1. Palo Alto (CA): Stanford University Press; 1960; p. 278–292.
   Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences (hardback). 2nd ed. Abingdon (UK): Routledge; 2016.
   Google Scholar
• Karatzoglou A. kernlab – an S4 Package for Kernel Methods in R. J Stat Softw. 2004;11(9):1–20.
   Google Scholar
• Sidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62(318):626–633.
   Web of Science ®Google Scholar
• Charkiewicz K, Jasinska E, Goscik J, et al. Angiogenic factor screening in women with mild preeclampsia – New and significant proteins in plasma. Cytokine. 2018;106:125–130.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89(2):770–775.
   PubMed Web of Science ®Google Scholar
• Kim SY, Ryu HM, Yang JH, et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci. 2007;22(5):873–877.
   PubMed Web of Science ®Google Scholar
• Salahuddin S, Lee Y, Vadnais M, et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197(1):28.e1–28.e6.
   Web of Science ®Google Scholar
• Nicolaides KH, Bindra R, Turan OM, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obst Gyn. 2005;27(1):13–17.
   Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
   PubMed Web of Science ®Google Scholar
• Kosiński P, Samaha RB, Bomba-Opoń DA, et al. Reference values for placental growth factor (PlGF) concentration and uterine artery Doppler pulsatility index (PI) at 11–13(+6) weeks of gestation in the Polish population. Ginekol Pol. 2014;85(7):488–493.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Dai K, Cui X, et al. Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia. Biomed Pharmacother. 2016;80:102–108.
   PubMed Web of Science ®Google Scholar
• Cullinan EB, Abbondanzo SJ, Anderson PS, et al. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. Proc Natl Acad Sci USA. 1996;93(7):3115–3120.
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Burns K, Schneider P, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity. 1997;6(1):79–88.
   PubMed Web of Science ®Google Scholar
• Vaughan JE, Walsh SW. Activation of NF-κB in placentas of women with preeclampsia. Hypertens Preg. 2012;31(2):243–251.
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Saito S, Rolinski J, et al. Activated T lymphocytes in pre-eclampsia. Am J Reprod Immunol. 2007;58(1):39–45.
   PubMed Web of Science ®Google Scholar
• Szarka A, Rigó J, Lázár L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 2010;11(1):59.
   PubMed Web of Science ®Google Scholar
• Chui A, Murthi P, Brennecke SP, et al. The expression of placental proteoglycans in pre-eclampsia. Gynecol Obstet Invest. 2012;73(4):277–284.
   PubMed Web of Science ®Google Scholar
• Said JM. The role of proteoglycans in contributing to placental thrombosis and fetal growth restriction. J Preg. 2011;2011:928381.
   PubMedGoogle Scholar
• Oh JS, Youm YS, Cho SD, et al. The expression of vascular endothelial growth factor and Syndecan-4 in cartilage from osteoarthritic knees. Bone Joint J. 2014;96–B(10):1319–1324.
   PubMed Web of Science ®Google Scholar
• Schanz A, Baston-Bust D, Krussel JS, et al. CXCR7 and syndecan-4 are potential receptors for CXCL12 in human cytotrophoblasts. J Reprod Immunol. 2011;89(1):18–25.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Oritani K, Miyoshi EK, et al. Syndecan-4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes. J Immunol. 1999;162(10):5940–5948.
   PubMed Web of Science ®Google Scholar
• Jeschke U, Hutter S, Heublein S, et al. Expression and function of galectins in the endometrium and at the human feto-maternal interface. Placenta. 2013;34(10):863–872.
   PubMed Web of Science ®Google Scholar
• van der Laan AM, Schirmer SH, de Vries MR, et al. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J. 2012;33(9):1076–1084.
   PubMed Web of Science ®Google Scholar
• Sturm A, Lensch M, André S, et al. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol. 2004;173(6):3825–3837.
   PubMed Web of Science ®Google Scholar
• Hutter S, Martin N, von Schönfeldt V, et al. Galectin 2 (gal-2) expression is downregulated on protein and mRNA level in placentas of preeclamptic (PE) patients. Placenta. 2015;36(4):438–445.
   PubMed Web of Science ®Google Scholar
• Janko C, André S, Munoz LE, et al. Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. Lupus. 2012;21(7):781–783.
   PubMed Web of Science ®Google Scholar
• Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4(1):17103.
   PubMed Web of Science ®Google Scholar